Astrazeneca annual total liabilities
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Total Liabilities Growth & History (AZN)
Astrazeneca's total liabilities was $65.36B for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $65.36B | $2.19B | +3.47% |
| 2024 | 2024-12-31 | $63.16B | $1.21B | +1.95% |
| 2023 | 2023-12-31 | $61.95B | $2.53B | +4.25% |
| 2022 | 2022-12-31 | $59.42B | −$6.65B | −10.07% |
| 2021 | 2021-12-31 | $66.08B | $14.98B | +29.33% |
| 2020 | 2020-12-31 | $51.09B | $4.31B | +9.21% |
| 2019 | 2019-12-31 | $46.78B | $174.0M | +0.37% |
| 2018 | 2018-12-31 | $46.61B | −$105.0M | −0.22% |
| 2017 | 2017-12-31 | $46.71B | $855.0M | +1.86% |
| 2016 | 2016-12-31 | $45.86B | $4.31B | +10.37% |
| 2015 | 2015-12-31 | $41.55B | — | — |
Astrazeneca quarterly total liabilities
Q4.17
Q2.18
Q4.18
Q2.19
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $65.46B | −$2.15B | −3.18% |
| Q1 2026 | 2026-03-31 | $66.63B | — | — |
| Q4 2025 | 2025-12-31 | $65.36B | $2.19B | +3.47% |
| Q3 2025 | 2025-09-30 | $68.48B | — | — |
| Q2 2025 | 2025-06-30 | $67.61B | $2.87B | +4.43% |
| Q4 2024 | 2024-12-31 | $63.16B | $1.21B | +1.95% |
| Q2 2024 | 2024-06-30 | $64.74B | $5.62B | +9.50% |
| Q4 2023 | 2023-12-31 | $61.95B | $2.53B | +4.25% |
| Q2 2023 | 2023-06-30 | $59.13B | −$1.50B | −2.48% |
| Q4 2022 | 2022-12-31 | $59.42B | −$6.65B | −10.07% |
| Q2 2022 | 2022-06-30 | $60.63B | $2.68B | +4.62% |
| Q4 2021 | 2021-12-31 | $66.08B | $14.98B | +29.33% |
| Q2 2021 | 2021-06-30 | $57.95B | $11.68B | +25.24% |
| Q4 2020 | 2020-12-31 | $51.09B | $4.31B | +9.21% |
| Q2 2020 | 2020-06-30 | $46.27B | −$547.0M | −1.17% |
| Q4 2019 | 2019-12-31 | $46.78B | $174.0M | +0.37% |
| Q2 2019 | 2019-06-30 | $46.82B | −$254.0M | −0.54% |
| Q4 2018 | 2018-12-31 | $46.61B | −$105.0M | −0.22% |
| Q2 2018 | 2018-06-30 | $47.07B | — | — |
| Q4 2017 | 2017-12-31 | $46.71B | — | — |
Astrazeneca total liabilities trends
Over the last five fiscal years, Astrazeneca's total liabilities increased from $51.09B to $65.36B, a change of $14.26B. The latest reported quarter, Q2 2026, shows $65.46B.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...